Revefenacin
FDA-approved product (solution, inhalation), marketed as Yupelri.
- Registered studies
- 20
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Airway obstruction
- Chronic obstructive pulmonary disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Anticholinergics
- FDA pharmacologic class
- Anticholinergic FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli47.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
20registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Revefenacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Tubocurarine ChlorideExisting use: Curare alkaloids51.4% AI-predicted activityagainst E. coliNo documented evidence found
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more51.4% AI-predicted activityagainst E. coli50+ registered studies
- BrigatinibExisting use: Neoplasm, Non-small cell lung carcinoma51.2% AI-predicted activityagainst E. coli48 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more51.1% AI-predicted activityagainst E. coli50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more51.0% AI-predicted activityagainst E. coli50+ registered studies
- EntrectinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma50.9% AI-predicted activityagainst E. coli46 registered studies
- DasatinibExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more50.8% AI-predicted activityagainst E. coli50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more50.5% AI-predicted activityagainst E. coli35 registered studies
- IvosidenibExisting use: Acute myeloid leukemia, Cholangiocarcinoma50.4% AI-predicted activityagainst E. coli50+ registered studies
- Thiamine HydrochlorideExisting use: Anemia (phenotype), Chronic kidney disease, Encephalopathy and 2 more50.4% AI-predicted activityagainst E. coli50+ registered studies
- VibegronExisting use: Overactive bladder, Polyuria, Urgency urinary incontinence and 1 more50.4% AI-predicted activityagainst E. coli16 registered studies
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma50.3% AI-predicted activityagainst E. coli3 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
NCT02772159 · start 2015-06
Registered record
- Registry ID
- NCT02772159
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- TD-4208
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-06
- Completion
- 2016-04
- Enrolment
- 9
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Obstructive Pulmonary Disease (COPD)InterventionTD-4208PhasePhase 1Registry statusCompletedA 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
NCT02040792 · start 2014-05
Registered record
- Registry ID
- NCT02040792
- Conditions
- COPD
- Interventions
- TD-4208; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-05
- Completion
- 2014-08
- Enrolment
- 355
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCOPDInterventionTD-4208; PlaceboPhasePhase 2Registry statusCompletedA 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
NCT02109172 · start 2014-04
Registered record
- Registry ID
- NCT02109172
- Conditions
- Chronic Obstructive Pulmonary Disease; COPD
- Interventions
- TD-4208; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-04
- Completion
- 2014-10
- Enrolment
- 64
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Obstructive Pulmonary Disease; COPDInterventionTD-4208; PlaceboPhasePhase 2Registry statusCompleted7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
NCT01704404 · start 2012-12
Registered record
- Registry ID
- NCT01704404
- Conditions
- COPD
- Interventions
- TD-4208; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-12
- Completion
- 2013-12
- Enrolment
- 62
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCOPDInterventionTD-4208; PlaceboPhasePhase 2Registry statusCompletedEffects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT03064113 · start 2011-05
Registered record
- Registry ID
- NCT03064113
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD
- Interventions
- Placebo; TD-4208 700 μg; TD-4208 350 μg; Ipratropium 500 μg
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2011-05
- Completion
- 2011-10
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Obstructive Pulmonary Disease, COPDInterventionPlacebo; TD-4208 700 μg; TD-4208 350 μg; Ipratropium 500 μgPhasePhase 2Registry statusCompleted